$NVO more pain ahead! Headed down to $46-55

$NVO more pain ahead! Headed down to $46-55

- NYSE:NVO was one of the hottest stocks of 2024 is now facing immense challenges by other healthcare companies in weight loss drug.

- With weak results, it sets up for disappointment for 1-2 quarters. Quick turnaround in experiments isn't feasible and would need considerable time to show promising results.

- It's better to put it on watchlist, attend earning call however it is likely that it might underperform FY 2025 or alteast first half of FY 2025.

Read More

Share:

Latest News